Prophylactic Human Vaccine Market– Regional Analysis
On the basis of region, theglobal ProphylacticHuman Vaccine Market is segmented into North America, Latin America,Europe, Asia Pacific, Middle East, and Africa.
Geographically, North America isprobable to lead in the global prophylactic human vaccine market, owing toreceiving large number of research grants by government. For instance, inSeptember 2018, GeoVax Labs, Inc., U.S.-based company recieved grant of US$2,442,307 by the U.S. Army Medical Research Acquisition Activity. The grant wasawarded as a cooperative agreement for novel Lassa Fever (LF) vaccine(GEO-LM01) development program. GEO-LM01 uses Modified Vaccinia Ankara (MVA)and Virus-Like Particle (VLP) vaccine platform that has been demonstrated to besafe and induce antibody responses in patients. Moreover, MVA-VLP platform has showneffective results in other cases such as GeoVax’s prophylactic HIV vaccine,GeoVax’s Ebola (EBOV) vaccine, and GeoVax’s Zika vaccine in its respectivepreclinical studies.
Prophylactic human vaccinesstimulate the immune response and are intended for ameliorating the effects offuture infection caused by pathogens in human beings. Novel vaccine developmenttechnologies such as viral-like particles are used in developing Hepatitis BVirus (HBV) vaccines, and Human Papilloma Virus (HPV) vaccines. For instance,in March 2014, CureVac AG received EUR 2 million Vaccine Prize from EuropeanCommission for its novel RNActive vaccine technology. This RNActive vaccinetechnology enables production of safe, efficacious, and cost-effective vaccinesthat are protected against elevated temperature as well as inadvertentfreezing.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2261
Prophylactic Human Vaccine Market– Drivers
Increasing number of pipelinestudies and rising involvement of key players for vaccine development is expectedto propel growth of the prophylactic human vaccine market during the forecastperiod. For instance, in October 2018, CureVac AG, announced to initiate doseescalation phase I clinical trial for CV7202 mRNA-based rabies vaccine. CV7202is a prophylactic vaccine encoding RABV-G, the rabies virus glycoprotein. Thiswill enable vaccinated individual's own cells to produce RABV-G protein, bywhich immune response gets triggered. This study is estimated to complete inJanuary 2021.
Moreover, in October 2018,Valneva SE announced progress in its Phase 1 program targeting a single-shotvaccine against Chikungunya. It is designed for prophylactic, active,single-dose immunization against Chikungunya in humans. The vaccine aims forlong-lasting protection and an anticipated safety profile similar to otherapproved vaccines for active immunization in adults and children.
Furthermore, rising initiativesby various scientists to develop innovative solutions to fight againstinfectious diseases is expected to drive growth of the market. For instance,VBI Vaccines Inc., in September 2018, announced formation of three Scientificand Clinical Advisory Boards (SABs) comprising leading experts in infectiousdisease and immuno-oncology research and vaccine development targetinghepatitis B, Cytomegalovirus (CMV), and Glioblastoma (GBM). This collaborationis expected to propel growth of the market, owing to enhanced vaccinedevelopment.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/prophylactic-human-vaccine-market-2261
Prophylactic Human Vaccine Market– Restraint
Significant barriers in thevaccine development such as virus diversity and limited number of animal modelsare estimated to hamper growth of the prophylactic human vaccine market. Forinstance, according to Gastroenterology, in October 2018, vaccine developmentrequires huge investment from various resources and is very challenging.Designing vaccine trials in human is difficult since following immunization thechances for develop an acute infection is very high. Therefore, anti-viraltreatment has to be offered immediately, which makes it a challenging task tomanage disease.
Europe region is also expected toperceive extensive growth in prophylactic human vaccine market, due to risinginitiatives by government for developing efficient and safe vaccines. Forinstance, in October 2017, the European Commission funded TRANSVAC, a newinfrastructure project. This project aims to rapidly develop effective vaccinesin order to address European health challenges and in turn increase thesustainability of EC vaccine projects in Europe. TRANSVAC offers high-qualitytechnical services to support development of prophylactic and therapeuticvaccines for both human and animal use.
The key players operating inprophylactic human vaccine market include, GlaxoSmithKline Plc., Merck &Co., Inc., Pfizer Inc., Janssen Pharmaceuticals, Inc., Altimmune, Inc., BharatBiotech International Limited, Serum Institute of India Pvt. Ltd., Sanofi PasteurSA, Shanghai BravoBio Co., Ltd., SK Chemicals Co., Ltd., Takeda PharmaceuticalCompany Limited, BiondVax Pharmaceuticals Ltd., and SK Chemicals Co., Ltd.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2261
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
